Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
The analysis of investment activity ratios reveals a consistent downward trend in asset utilization efficiency across all measured metrics from early 2022 through early 2026. While a brief period of improvement was observed in late 2022, the subsequent trajectory indicates a gradual decline in the company's ability to generate revenue relative to its asset and equity bases.
- Net Fixed Asset Turnover
- A peak efficiency level of 5.12 was reached in October 2022, followed by a sustained decline. The ratio decreased to 4.50 by September 2024 and reached a low of 4.22 in December 2025, before ending at 4.24 in March 2026. This downward movement suggests that the growth in net fixed assets has outpaced the growth in revenue, or that existing fixed assets are being utilized less intensively.
- Total Asset Turnover
- Total asset utilization followed a similar pattern, peaking at 0.49 in October 2022. The ratio remained relatively stable around 0.46 through mid-2023 but began a steady descent thereafter, concluding at 0.40 in March 2026. This indicates a general reduction in the overall efficiency of the total asset base in generating top-line growth.
- Equity Turnover
- Equity turnover exhibited a peak of 1.04 in April 2023. Following this point, a clear downward trend emerged, with the ratio falling to 0.86 by June 2024 and reaching 0.83 in December 2025, ultimately settling at 0.87 in March 2026. The contraction in this ratio reflects a decrease in the volume of sales generated per unit of shareholder equity.
The synchronized decline across net fixed asset, total asset, and equity turnover ratios suggests a systemic shift in the company's investment profile. The data points toward a period of asset expansion or equity accumulation that has not been matched by a proportional increase in revenue, leading to diminished activity ratios over the analyzed timeframe.
Net Fixed Asset Turnover
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Net fixed asset turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Property, plant and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of long-term activity ratios reveals a general decline in the efficiency of fixed asset utilization over the period from April 2022 to March 2026. While revenues experienced periodic fluctuations, the steady expansion of the net property, plant, and equipment base has led to a downward trajectory in the net fixed asset turnover ratio.
- Net Fixed Asset Turnover Trend
- The net fixed asset turnover ratio reached a peak of 5.12 in October 2022 before entering a long-term decline. Throughout 2023 and 2024, the ratio largely stabilized between 4.50 and 4.74. However, a more pronounced downward trend emerged in 2025, with the ratio falling to a low of 4.22 by December 31, 2025, before slightly recovering to 4.24 in March 2026. This overall decrease suggests that each dollar invested in fixed assets is generating less revenue than in previous periods.
- Fixed Asset Accumulation
- A consistent increase in net property, plant, and equipment is observed, rising from 8,448 million USD in April 2022 to 10,658 million USD by March 2026. This steady growth in the asset base indicates ongoing capital investment and capacity expansion.
- Revenue Correlation
- Revenues remained relatively volatile but generally range-bound, fluctuating between a low of 10,345 million USD in March 2024 and a peak of 12,215 million USD in December 2025. Because the growth in the net fixed asset base outpaced the growth in revenues over the long term, the resulting turnover ratio declined.
- Operational Insight
- The divergence between increasing fixed assets and stagnating or slowly growing revenues indicates a period of capacity building. The decline in the turnover ratio suggests that the incremental investments in property, plant, and equipment have not yet translated into a proportional increase in top-line revenue growth, reflecting a lag between capital expenditure and operational yield.
Total Asset Turnover
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Total asset turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a general downward trajectory over the analyzed period, declining from a peak of 0.49 in October 2022 to 0.40 by March 2026. This trend indicates a reduction in the efficiency with which the company generates revenue relative to its total investment in assets.
- Asset Base Expansion
- A consistent increase in the total asset base is observed, rising from 92,747 million USD in April 2022 to 113,281 million USD by March 2026. This steady growth suggests significant capital expenditures or acquisitions aimed at expanding the company's operational capacity.
- Revenue Performance
- Revenues demonstrated a lack of sustained growth, fluctuating within a range of approximately 10,345 million USD to 12,215 million USD throughout the period. The revenue levels in March 2026 (11,005 million USD) remain lower than the levels observed in April 2022 (11,818 million USD), despite the substantial increase in the asset base.
- Efficiency Correlation
- The decline in the total asset turnover ratio is directly attributable to the divergence between asset growth and revenue generation. While assets grew by approximately 22% over the period, revenues did not experience a corresponding increase. The contraction of the ratio from 0.49 to 0.40 highlights a diminishing return on the total asset investment, suggesting that newly added assets have not yet contributed proportionally to top-line growth.
Equity Turnover
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Equity turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance regarding investment activity exhibits a clear divergence between the growth of the capital base and the generation of revenue. While shareholders' equity has expanded consistently, revenue growth has not kept pace, leading to a gradual decline in the efficiency of equity utilization over the observed period.
- Revenue Performance
- Quarterly revenues demonstrate a pattern of stagnation and volatility rather than a sustained growth trend. Values generally fluctuated between a minimum of 10,345 million US$ in March 2024 and a maximum of 12,215 million US$ in December 2024, indicating a lack of strong top-line expansion over the analyzed timeframe.
- Equity Growth
- A steady increase in total shareholders' equity is observed, rising from 40,956 million US$ in April 2022 to 51,934 million US$ by March 2026. This expansion represents a significant increase in the net asset base, reflecting a consistent accumulation of equity throughout the period.
- Equity Turnover Trend
- The equity turnover ratio shows a notable downward trajectory. After reaching a peak of 1.04 in April 2023, the ratio declined steadily, dropping below 0.90 for the majority of 2024 and 2025. The ratio reached a low of 0.83 in December 2025 before slightly recovering to 0.87 in March 2026.
- Operational Efficiency Insight
- The reduction in the equity turnover ratio indicates a decrease in the ability to generate sales relative to the equity invested. The trend suggests that the growth in the equity base is outpacing revenue growth, resulting in lower capital productivity and a diminished capacity to convert shareholders' equity into top-line revenue.